Jazz Pharmaceuticals PLC - Detailed Introduction, Company Background, Business Scope, Financial Data, and Market Performance

More Details of Jazz Pharmaceuticals PLC Company

Jazz Pharmaceuticals PLC is a biotechnology company. The Company is engaged in developing medicines for people with serious diseases. The Company’s lead marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Xyrem (sodium oxybate) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Defitelio (defibrotide sodium) AND Vyxeos (daunorubicin and cytarabine) liposome for injection. The Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution product is for the treatment of cataplexy or excessive daytime sleepiness (EDS), in patients with narcolepsy seven years of age and older. The Xyrem (sodium oxybate) oral solution product is for the treatment of cataplexy or EDS in patients with narcolepsy seven years of age and older. The Defitelio (defibrotide sodium) product is for the treatment of hepatic veno-occlusive disease (VOD).

Jazz Pharmaceuticals PLC Info



Ticker SymbolJAZZ

Company nameJazz Pharmaceuticals PLC

IPO dateJan 18, 2012

CEOMs. Renee D. Gala

Number of employees2800

Security typeOrdinary Share

Fiscal year-endJan 18

AddressFifth Floor, Waterloo Exchange

CityDUBLIN

Stock exchangeNASDAQ Global Select Consolidated

CountryIreland

Postal code- -

Phone35316347800

Websitehttps://www.jazzpharma.com/

Ticker SymbolJAZZ

IPO dateJan 18, 2012

CEOMs. Renee D. Gala

Company Executives of Jazz Pharmaceuticals PLC



Name

Name/Position

Position

Shareholding

Change

Mr. Seamus C. Mulligan

Independent Director

1.28M

+0.28%

Mr. Bruce C. Cozadd

Chairman of the Board

307.81K

-1.76%

Ms. Renee D. Gala

President, Chief Executive Officer, Director

48.20K

+64.00%

Dr. Robert Iannone, M.D.

Executive Vice President, Global Head - Research and Development, Chief Medical Officer

31.28K

--

Mr. Kenneth W. (Ken) O'Keefe

Independent Director

29.39K

+6.15%

Ms. Neena M. Patil, J.D.

Executive Vice President, Chief Legal Officer

21.63K

-15.90%

Mr. Philip L. Johnson

Chief Financial Officer, Executive Vice President

15.00K

--

Dr. Norbert G. Riedel, Ph.D.

Independent Director

13.92K

+13.93%

Ms. Anne O'Riordan

Independent Director

12.77K

+15.38%

Mr. Rick E. Winningham

Lead Independent Director

10.66K

+19.00%

Name

Name/Position

Position

Shareholding

Change

Mr. Seamus C. Mulligan

Independent Director

1.28M

+0.28%

Mr. Bruce C. Cozadd

Chairman of the Board

307.81K

-1.76%

Ms. Renee D. Gala

President, Chief Executive Officer, Director

48.20K

+64.00%

Dr. Robert Iannone, M.D.

Executive Vice President, Global Head - Research and Development, Chief Medical Officer

31.28K

--

Mr. Kenneth W. (Ken) O'Keefe

Independent Director

29.39K

+6.15%

Ms. Neena M. Patil, J.D.

Executive Vice President, Chief Legal Officer

21.63K

-15.90%

Revenue Breakdown

Currency: USDUpdated: Mon, Oct 6

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

By BusinessUSD

Name

Revenue

Proportion

Xywav

415.32M

39.72%

Epidiolex/epidyolex

251.73M

24.07%

Rylaze

100.66M

9.63%

Zepzelca

74.54M

7.13%

High-sodium oxybate AG royalty revenue

54.14M

5.18%

Other

149.32M

14.28%

By RegionUSD

Name

Revenue

Proportion

United States

936.28M

89.54%

Europe

82.76M

7.91%

All Others

26.67M

2.55%

By Business

By Region

By BusinessUSD

Name

Revenue

Proportion

Xywav

415.32M

39.72%

Epidiolex/epidyolex

251.73M

24.07%

Rylaze

100.66M

9.63%

Zepzelca

74.54M

7.13%

High-sodium oxybate AG royalty revenue

54.14M

5.18%

Other

149.32M

14.28%

Shareholding Stats

Updated: Thu, Oct 16

Shareholders

Shareholder Types

Shareholders

Proportion

The Vanguard Group, Inc.

10.00%

BlackRock Institutional Trust Company, N.A.

8.61%

LSV Asset Management

4.21%

Capital World Investors

4.19%

Dimensional Fund Advisors, L.P.

4.18%

Other

68.80%

Shareholders

Proportion

The Vanguard Group, Inc.

10.00%

BlackRock Institutional Trust Company, N.A.

8.61%

LSV Asset Management

4.21%

Capital World Investors

4.19%

Dimensional Fund Advisors, L.P.

4.18%

Other

68.80%

Shareholder Types

Shareholders

Proportion

Investment Advisor

52.52%

Investment Advisor/Hedge Fund

34.31%

Hedge Fund

8.96%

Research Firm

3.43%

Individual Investor

3.07%

Pension Fund

2.79%

Venture Capital

1.89%

Bank and Trust

0.96%

Sovereign Wealth Fund

0.12%

Institutional Shareholding



Updated: Wed, Oct 1

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q3

1191

64.20M

105.84%

-4.58M

2025Q2

1199

63.76M

105.11%

-6.47M

2025Q1

1235

63.66M

105.15%

-6.35M

2024Q4

1202

62.66M

103.17%

-6.51M

2024Q3

1172

61.48M

99.60%

-6.16M

2024Q2

1167

61.28M

97.21%

-6.97M

2024Q1

1163

63.08M

101.15%

-2.43M

2023Q4

1156

61.76M

98.11%

-3.48M

2023Q3

1158

61.08M

96.76%

-4.05M

2023Q2

1197

61.00M

95.34%

-4.11M

Shareholder Activity



Name

Shares Held

Proportion

Change

Chg %

Date

The Vanguard Group, Inc.

6.07M

10%

+73.43K

+1.22%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

5.22M

8.61%

+11.23K

+0.22%

Jun 30, 2025

LSV Asset Management

2.55M

4.21%

+87.58K

+3.55%

Jun 30, 2025

Capital World Investors

2.54M

4.19%

+616.73K

+31.99%

Jun 30, 2025

Dimensional Fund Advisors, L.P.

2.54M

4.18%

+209.41K

+8.99%

Jun 30, 2025

State Street Investment Management (US)

1.94M

3.19%

-31.20K

-1.59%

Jun 30, 2025

EcoR1 Capital, LLC

1.71M

2.81%

--

Jun 30, 2025

Fuller & Thaler Asset Management Inc.

1.63M

2.69%

+297.95K

+22.39%

Jun 30, 2025

JP Morgan Asset Management

1.55M

2.55%

+46.92K

+3.12%

Jun 30, 2025

Columbia Threadneedle Investments (US)

1.54M

2.54%

+186.67K

+13.80%

Jun 30, 2025

Related ETFs



Updated: Sun, Nov 2

Name

Proportion

LSV Disciplined Value ETF

27.6%

Cambria Cannabis ETF

5.46%

iShares U.S. Pharmaceuticals ETF

2.95%

Invesco Pharmaceuticals ETF

2.86%

First Trust Health Care Alphadex Fund

2.63%

SPDR S&P Pharmaceuticals ETF

2.5%

First Trust NASDAQ Pharmaceuticals ETF

2.28%

Abacus FCF International Leaders ETF

2.02%

Alger Russell Innovation ETF

2%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

1.87%

LSV Disciplined Value ETF

Proportion27.6%

Cambria Cannabis ETF

Proportion5.46%

iShares U.S. Pharmaceuticals ETF

Proportion2.95%

Invesco Pharmaceuticals ETF

Proportion2.86%

First Trust Health Care Alphadex Fund

Proportion2.63%

SPDR S&P Pharmaceuticals ETF

Proportion2.5%

First Trust NASDAQ Pharmaceuticals ETF

Proportion2.28%

Abacus FCF International Leaders ETF

Proportion2.02%

Alger Russell Innovation ETF

Proportion2%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

Proportion1.87%

Dividend



A total of 0.00 USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

No Data

Stock Split



Date

Type

Ratio

No Data

Date

Type

Ratio

No Data